The Expression Characteristics And Clinicopathological Significance Of TRAIL,DR5 And PAKT In Human Laryngeal Squamous Carcinoma

Objective:SABC immunohistochemistry method to detect the expression of pAKT,TRAIL and DR5 in laryngeal normal tissues and LSCC.The correlation of each score according to the intensity and percentage of labeled cells or intercellular substance with relevant clinical data was statistically analyzed.to explore the relationships between each factor and each clinical pathological characteristic of LSCC such as age,sex,location,differentiation and lymph node metastasis,so as to estimate the roles of above factors in the occurrence and development of LSCC,and then try to find the possible predictive and prognostic factors of LSCC and supply the theoretic bases for new targets of LSCC treatmentMethods:All of the formerly paraffin-section were from Department of Pathology,in Hebei North University first affiliated hospital over the past decade.We used illustrate the mechanism of the effect of TRAIL on LSCC,Including 68 cases of paraffin material with laryngeal carcinoma,and 35 cases of normal laryngeal mucosa.It shows the expression and clinical pathological features of TRAIL,DR5 and pAKT in LSCC and normal laryngeal mucosa.The correlation of each score according to the intensity and percentage of labeled cells,intercellular substance with relevant clinical data was statistically analyzed.Results:1.The TRAIL expressed both in tissues of LSCC and laryngeal normal tissues in the experiment of the immunohistochemistry.Results showed the expression of TRAIL(39.7%)in LSCC were significantly lower than normal laryngeal mucosa(71.4%)(P < 0.05);Its expression is closely related clinical stages.The TRAIL expression was higher in ?and ?stages,but lower in ?and ?stages(P<0.05),related to differentiation,not related to age,gender,smoking status,location or metastasis(P>0.05).2.The DR5 expressed both in tissues of LSCC and laryngeal normal tissues in the experiment of the immunohistochemistry.The expression of DR5(55.9%)in LSCC were not statistically different than normal laryngeal mucosa(57.1%)(P>0.05);The DR5 expression was higher in ? and ? stages,but lower in ? and ? stages(P<0.05),Its expression is closely related clinical stages,not related to age,gender,smoking status,location,differentiation or metastasis(P>0.05).Consistency Check indicated the consistency,the positive relationship could be seen between TRAIL and DR5(P<0.05).3.The pAKT expressed both in tissues of LSCC and laryngeal normal tissues in the experiment of the immunohistochemistry.Results showed the expression of pAKT(80.9%)in LSCC were significantly higher than normal laryngeal mucosa(20.0%)(P<0.05);The positive rates of pAKT in LNM and without LNM were 94.4%,65.6%.The positive rate of pAKT protein expression in LNM was obviously higher than those without LNM(P<0.05).The pAKT expression is not related to age,sex,smoking status,location,differentiation or stages(P > 0.05).Consistency check indicated the consistency,the negative correlation could be seen between TRAIL and pAKT(P<0.05).Conclusions:1.The expression rate of pAKT was significantly higher in LSCC than that in NM.The abnormal high expression of pAKT in LSCC may be related to the development of LSCC.2.The expression rate of TRAIL was significantly lower in LSCC than that in NM.The level of TRAIL related with different clinical staging and different pathological stage.The abnormal low expression of TRAIL in LSCC may be related to the development of LSCC.The Negative relationship could be seen between p AKT and TRAIL.3.TRAIL is essentially expressed in laryngeal cancer,and in laryngeal normal tissues.But expression degree is different in different tissues.This may explain the difference in their sensitivity to TRAIL to a certain extent.The level of TRAIL and DR5 related with different pathological stages,and different clinical staging.4.The test of TRAIL,DR5 and pAKT protein may have significant prognostic value to assessing the degree of malignancy and clinical information probability of LSCC.TRAIL may enhances the sensitivity by protein kinase B(PKB)/Akt signaling pathway of LSCC to and investigate the relevant mechanism.TRAIL is expected to be a new indicator for prognosis of patients with malignant tumor such as laryngeal squamous cell carcinoma or a target for tumor therapy.